Prelude Therapeutics (NASDAQ:PRLD) and Surrozen (NASDAQ:SRZN) Head to Head Survey

Prelude Therapeutics (NASDAQ:PRLD) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Volatility and Risk

Prelude Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Profitability

This table compares Prelude Therapeutics and Surrozen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Surrozen	-2,885.33%	N/A	-93.62%

Analyst Ratings

This is a summary of recent recommendations for Prelude Therapeutics and Surrozen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1	1	5	0	2.57
Surrozen	1	1	4	1	2.71

Prelude Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 168.40%. Surrozen has a consensus target price of $48.33, suggesting a potential upside of 106.20%. Given Prelude Therapeutics’ higher probable upside, equities research analysts clearly believe Prelude Therapeutics is more favorable than Surrozen.

Valuation and Earnings

This table compares Prelude Therapeutics and Surrozen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14 million	21.43	-$99.50 million	($0.73)	-4.47
Surrozen	$3.48 million	78.20	-$242.03 million	($40.55)	-0.58

Prelude Therapeutics has higher revenue and earnings than Surrozen. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Prelude Therapeutics beats Surrozen on 10 of the 15 factors compared between the two stocks.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.